Impact of Neoadjuvant Chemotherapy on SATB2 Expression in Colorectal Carcinomas: SATB2 Positivity is Preserved in Most Cases, but Down-Expressed in Effective Cases of Chemotherapy.

MLA

Asahina, Yuichi, et al. “Impact of Neoadjuvant Chemotherapy on SATB2 Expression in Colorectal Carcinomas: SATB2 Positivity Is Preserved in Most Cases, but Down-Expressed in Effective Cases of Chemotherapy.” International Journal of Surgical Pathology, vol. 31, no. 1, Feb. 2023, pp. 46–55. EBSCOhost, https://doi.org/10.1177/10668969221088881.

APA

Asahina, Y., Hashimoto, H., Aihara, M., Noie, T., & Morikawa, T. (2023). Impact of Neoadjuvant Chemotherapy on SATB2 Expression in Colorectal Carcinomas: SATB2 Positivity is Preserved in Most Cases, but Down-Expressed in Effective Cases of Chemotherapy. International Journal of Surgical Pathology, 31(1), 46–55. https://doi.org/10.1177/10668969221088881

Chicago

Asahina, Yuichi, Hirotsugu Hashimoto, Makoto Aihara, Tamaki Noie, and Teppei Morikawa. 2023. “Impact of Neoadjuvant Chemotherapy on SATB2 Expression in Colorectal Carcinomas: SATB2 Positivity Is Preserved in Most Cases, but Down-Expressed in Effective Cases of Chemotherapy.” International Journal of Surgical Pathology 31 (1): 46–55. doi:10.1177/10668969221088881.